There was no significant difference in any of the efficacy endpoints for patients with high‐grade B‐cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements. This evidence concerns the gene BCL6 and B-cell non-Hodgkin lymphoma.